feasibility of Innovative photography technology (The VISIA facial imaging system) to monitor the effect of 5-flurouracil treatment for people with solar/actinic damage to their face.

Not Applicable

Completed

• Conditions: facial solar (actinic) damage; Skin - Dermatological conditions

• Registration Number: ACTRN12618001207202
• Lead Sponsor: The University of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-18
• Study Completion: 2019-06-05
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

over the age of 18 years old, able to give informed consent, and about to commence 5-flurouracil treatment to face/scalp for solar/actinic damage to their skin.

Exclusion Criteria

Patients that have had field-treatment with 5-flurouracil, imiquimod, diclofenac sodium, ingenol mebutate or PDT within the last 12months or those who have periodically spot-treat keratinocyte lesions under the care of their dermatologist or GP within the last 12-months. Patients who would normally carry-out follow-up with their GP (for any reason including rural/remote home address, limited mobility etc.) will also be excluded in the interests of having standardised follow-up for study participants. Should at any time during the study period the clinician elect to cease treatment or perform alternate treatment (e.g. surgical) the participant will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assess the suitability of the VISIA Deluxe Imaging System to measure signs of photo damage/photo-aging in patients undergoing treatment with 5-fluroruracil for actinic/solar damage to the scalp/face.<br>This is done by comparing statistical significance testing of quantitative scoring provided by the VISIA, compared to clinical examination of participants skin, e.g. assessing surface scale and keratin, and presence of dermoscopic characteristics e.g. rosettes and strawberry pattern.<br>[2 weeks post commencing treatment<br>]

Secondary Outcome Measures

Name	Time	Method
Assess the suitability of the VISIA Deluxe Imaging System to measure signs of photo damage/photo-aging in patients undergoing treatment with 5-fluroruracil for actinic/solar damage to the scalp/face.<br>This is done by comparing statistical significance testing of quantitative scoring provided by the VISIA, compared to clinical examination of participants skin, e.g. assessing surface scale and keratin, and presence of dermoscopic characteristics e.g. rosettes and strawberry pattern.[at 4-6 weeks post treatment and 12 weeks post treatment]